BeOne secured second position in both innovation and invention in the 2025 China Pharmaceutical Innovation Index, reflecting its progress across innovative drug registrations, pipeline expansion, and global execution. Sustained R&D investment is fueling continuous innovation, with clinical and commercial successes across domestic and international markets reflecting the company’s strength in R&D efficiency, productivity, and global execution.
BeOne’s leadership is primarily underpinned by its deep R&D capabilities, breakthrough commercialization of flagship products, and accelerating global footprint. The company consistently ranks first in R&D spending among domestic peers, with R&D investment accounting for approximately 52% of revenue in 2024, laying a robust foundation for its innovation engine through sustained, disciplined investment. Driven by the global expansion of its best-in-class BTK inhibitor zanubrutinib (Brukinsa), BeOne delivered strong financial performance in 2024, generating RMB 27.2 billion (USD $3.84 billion) in revenue, up more than 40% year-on-year, and reinforcing its position as a global leader in oncology therapeutics.
The company has established a dual-pillar product architecture centered around zanubrutinib and its PD-1 inhibitor tislelizumab (Tevimbra). In 2024, zanubrutinib reached global sales of RMB 18.7 billion (USD $2.6 billion), ranking second globally and first in China in the BTK inhibitor class. Tislelizumab generated approximately RMB 3.5 billion (USD $493 million) in sales, placing it among the top five PD-1 therapies in China. Together, these products continue to consolidate BeOne’s leadership across hematologic and solid tumors.
In hematology, zanubrutinib achieved a pivotal milestone as the first and only BTK inhibitor globally approved for relapsed/refractory follicular lymphoma (R/R FL), marking a shift toward a “chemotherapy-free era” in FL treatment. The Phase II ROSEWOOD trial demonstrated that zanubrutinib plus obinutuzumab delivered significant benefits over the control arm across objective response rate (ORR), complete repose (CR) rate, and PFS, with a median PFS of 28.0 months and extended time to next treatment. Post-hoc analyses further showed that over 60% of R/R FL patients achieved greater PFS improvements versus their prior line of therapy, regardless of the number of previous treatments. The regimen has been included in the 2024 Chinese Society of Clinical Oncology and National Comprehensive Cancer Network guidelines, and zanubrutinib secured NRDL renewal with an expanded FL indication, enhancing access for patients with B-cell non-Hodgkin lymphoma. In parallel, BeOne advanced its global regulatory submissions for zanubrutinib in Waldenström macroglobulinemia, chronic lymphocytic leukemia, and mantle cell lymphoma across Japan, Thailand, India, and other markets. The drug is now approved in more than 70 markets worldwide. Complementing its BTK portfolio, BeOne is advancing two late-stage, differentiated next-generation assets a novel BCL2 inhibitor sonrotoclax and the BTK degrader BGB-16673 both with strong potential to become future growth engines.
BeOne has demonstrated strong momentum in solid tumors. Tislelizumab has achieved key regulatory progress across China, the U.S. and Europe, with continued expansion into additional indications such as lung and gastric cancers. It has also broadened its footprint in countries aligned with the Belt and Road Initiative, for example across parts of Southeast Asia, South Asia, the Middle East, and Africa.
BeOne’s HER2 bispecific antibody Zanidatamab (Baihe’an), one of the most advanced domestically developed HER2 bispecifics in China, has demonstrated compelling efficacy in second-line HER2-high biliary tract cancer. It has received multiple innovation designations in both China and the U.S., positioning BeOne at the forefront of innovation in this hard-to-treat tumor type. BeOne’s pipeline has evolved from an immuno-oncology–centric portfolio into a diversified innovation platform spanning lung, breast, gynecologic, and gastrointestinal cancers, supported by multi-modality technologies including ADCs, multi-specific antibodies, targeted protein degraders, and next-generation small molecules.
Beyond oncology, BeOne continues to broaden its external partnerships to enrich its pipeline and explore emerging therapeutic areas. Through a collaboration exceeding USD 253 million with CSPC Pharma, the company obtained global rights to the MAT2A inhibitor SYH2039, which holds promise as a next-wave oncology asset. Meanwhile, BeOne’s internally developed IRAK4 degrader BGB-45035 demonstrated meaningful clinical activity in autoimmune dermatologic diseases, signaling the company’s innovation potential beyond cancer.
BeOne’s sustained innovation momentum is not solely driven by high investment and a strong pipeline, but by its science-centered, globally-oriented innovation model. With systematic R&D planning and a rapidly advancing globalization strategy, the company is accelerating the transition of China’s original innovation from “follower” to “leader,” redefining the presence of Chinese pharmaceutical innovation on the global stage.
